Effects of Capros in Patients With Type-1 Diabetes

There are a total of 4 study visits,over the course of 12 weeks. These visits will occur on
weeks 1, 4, 8, and 12. At each study visit the the following will be recorded: Age, Sex,
Pulse, height, weight, CGM real time measurement and the following non-medical information
will be recorded: Address, Phone number and Email address ( will be recorded at the first
visit and will be asked if anything has changed at the reoccurring visits). The following
will happen at each visit:

Visit 1 (Week 0): The subject will be presented with informed consent. Data will be collected
on a data collection sheet, a finger stick for A1C will be obtained (if not completed as
SoC), Continuous Glucose Monitoring will be downloaded, UPT for WCBP will be performed, the
subject will be given a 4-week supply of the Capros supplement and a subject diary. The
subject will be given a subject diary to document their morning/evening sugar and the time of
when participants take the supplements. The subject will be asked to bring in the diary to
each follow-up visit to check for compliance verification.

Visit 2 and 3 (Week 4 and 8): The following activities will take place during these visits:
AE review, concomitant medications review, weight, vital signs, CGM download, pill count and
distribution, collect previous diary and provide new.

Visit 4 (Week 12): The following activities will take place during these visits: AE review,
concomitant medications review, weight, vital signs, CGM download, pill count, collect
previous diary. Also, at this visit, a finger stick for A1C (if not completed as SoC), no
further distribution of supplements.

Taking the supplement: After receiving the supplement, the subject is instructed to take 2
capsules per day by mouth, once with food around lunchtime and once with food around dinner
time for a total of 12 weeks. The subjects will be asked to keep all empty bottles/ any
remaining Capros supplements and bring them to each follow-up visit for a compliance check.
Participants will receive a new 4-week supply of supplements at study visits 2 and 3.

Risks for participating in this study are extremely low. Capros is a dietary supplement
derived from the Indian Gooseberry, and contains no artificial ingredients, is non-toxic and
is safely tolerated among humans. Capros is currently sold over the counter in the U.S. and
has no known side effects; however an allergic reaction to the supplement is possible.

There is a potential risk for hypoglycemia while taking this supplement. In the even that
this occurs, subjects are instructed to follow their primary care physician instructions for
this and record it on their data log.

This is not a treatment study so subjects may have no direct benefit while taking the
supplement. The investigators are looking to monitor and observe if any changes take place
with participants blood sugar level over the course of the study.

Inclusion Criteria:

- Subjects must be 10 - 60 yrs. of age

- Type 1 Diabetes using Continuous Glucose Monitoring (CGM) for at least the last 3
months

- Less than 10% variation in prescribed long acting dosages in the previous 3 months

Exclusion Criteria:

- Individuals who are deemed unable to understand the procedures, risks and benefits of
the study, i.e. informed consent will be excluded from the study

- Females who are pregnant

- Individuals who are therapeutically immuno-compromised

- Prisoners

- Anyone with a known allergy to amla fruit

- Current use of any of the following medications will result in exclusion:

- Steroids (Prednisone, etc.)

- Immunosuppressants

- Accutane (last 6 months)